Abstract
BackgroundNigeria is ranked in the top five countries for tuberculosis deaths worldwide. This study investigated the mycobacterial agents associated with presumptive clinical pulmonary tuberculosis (TB) in Nigeria and evaluated the pattern and frequency of mycobacterial infections over twelve calendar months period.MethodsSputum samples from 1,603 consecutive new cases with presumptive diagnosis of TB were collected from August 2010 to July 2011. All sputum samples were incubated for detection of mycobacterial growth and those with positive acid fast bacilli (AFB) growth were tested to detect mycobacterium tuberculosis (MTB) complex and characterized to differentiate between MTB complex species. Cultures suggestive of Non-tuberculous mycobacterial infections (NTM) were sub-cultured and characterized.ResultsOf the 1,603 patients screened, 444 (28%) culture-positive cases of pulmonary tuberculosis were identified. Of these, 375 (85%) were due to strains of MTB complex (354 cases of M. tuberculosis, 20 M. africanum and one case of M. bovis) and 69 (15%) were due to infection with NTM. In contrast to the MTB complex cases, the NTM cases were more likely to have been diagnosed during the calendar months of the Harmattan dust season (OR = 2.34, 1.28–4.29; p = 0.01), and aged older than 35 years (OR = 2.77, 1.52–5.02, p = 0.0007), but less likely to have AFB identified on their sputum smear (OR = 0.06, 0.02–0.14, p<0.0001). Among those with NTM infection, cases 35 years or younger were more likely to have co-infection with HIV (3.76, 1.72–8.22; p = 0.0009) compared to those older than 35 years.InterpretationThe high proportion of younger patients with clinical pulmonary TB due to NTM and co-infection with HIV and the likely role of the seasonal dust exposure in the occurrence of the disease, present novel public health challenges for prevention and treatment.
Highlights
The frequency of pulmonary disease from non-tuberculous mycobacterium (NTM) is reportedly on the rise in Europe, North America, Asia and Southern Africa [1]
A prospective evaluation of a cohort of 721 HIV positive patients in Abidjan, Cote d’Ivoire, Sub-Saharan Africa found the incidence of NTM infection was 9.7 times higher among patients with baseline CD4 cell counts less than 100 cells/mm3 compared to patients with CD4 cell counts above 100 cells/mm3
The risk of reactivation of latent mycobacterial infections including NTMs is found to be higher in patients receiving treatment with tumor necrosis factor inhibitors like infliximab and etanercept and this is becoming more prevalent in Europe and United States [13]
Summary
The frequency of pulmonary disease from non-tuberculous mycobacterium (NTM) is reportedly on the rise in Europe, North America, Asia and Southern Africa [1]. In sub-Saharan Africa, information on the extent of the burden of pulmonary disease from non-tuberculous mycobacteria (NTM) is lacking due to limitations in tools for mycobacterial species identification. Studies conducted as far back as the late 1950s and early 1960s using traditional tools for identifying mycobacterial groups based on certain characteristics like speed of growth and morphology, have reported the isolation of NTM from both tuberculosis patients and the general public in some African countries including Nigeria. The risk of reactivation of latent mycobacterial infections including NTMs is found to be higher in patients receiving treatment with tumor necrosis factor inhibitors like infliximab and etanercept and this is becoming more prevalent in Europe and United States [13]. This study investigated the mycobacterial agents associated with presumptive clinical pulmonary tuberculosis (TB) in Nigeria and evaluated the pattern and frequency of mycobacterial infections over twelve calendar months period
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
